GenScript is a global biotechnology group. GenScript’s businesses encompass four major categories based on its leading gene synthesis technology, including operation as a Life Science CRO, enzyme and synthetic biology products, biologics development and manufacturing, as well as cell therapy.
Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 300,000 customers from over 160 countries and regions around the world have used GenScript’s premier, convenient, and reliable products and services.
GenScript currently has more than 3000 employees globally, 33% of whom hold master’s and/or Ph.D. degrees. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis and bioinformatics, including more than 70 patents and over 200 patent applications. As of January 2019, GenScript's products and services have been cited by 36,500 scientific papers worldwide.
GenScript is committed to striving towards its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.
For more information, visit www.genscript.com
With more than 130 years of experience, Dr. Paul Lohmann® is a German expert in salt manufacturing and provides DPL-BioPharm Salts for the biopharmaceutical industry. These salts act as nutrients for cell cultures, as buffering and post-harvest processing agents within upstream processing. For downstream processing various acetates, citrates, phosphates and sulfates enable efficient bioprocesses for separation, precipitation and purification.
Thermo Fisher Scientific provides industry-leading pharma services solutions for drug development, clinical trial logistics and commercial manufacturing to customers through our Patheon brand. With more than 55 locations around the world, we provide integrated, end-to-end capabilities across all phases of development, including API, biologics, viral vectors, cGMP plasmids, formulation, clinical trials solutions, logistics services and commercial manufacturing and packaging. We give pharma and biotech companies of all sizes instant access to a global network of facilities and technical experts across the Americas, Europe, Asia and Australia. Our global leadership is built on a reputation for scientific and technical excellence. We offer integrated drug development and clinical services tailored to fit your drug development journey through our Quick to CareTM program. As a leading pharma services provider, we deliver unrivaled quality, reliability and compliance.
Together with our customers, we’re rapidly turning pharmaceutical possibilities into realities. In APAC, currently we have biologics manufacturing site based in Brisbane, Australia. In 2022, we will expand our presence in APAC and launch Biologics and Sterile fill finish site in Hangzhou, China and Sterile fill finish site in Singapore.
For more information, please visit our booth.
FUJIFILM has been actively pursuing reinforcement of business in the fields of biomedical and healthcare. By leveraging FUJIFILM Group’s collective bio-related technologies, including FUJIFILM Wako Pure Chemical and FUJIFILM Irvine Scientific, FUJIFILM continues to accelerate the growth and provide a broad product portfolio in bio-medical through synergies and collaborations.
FUJIFILM Wako Pure Chemical (FFWK) is a world-leading supplier of high purity chemicals and reagents based in Japan. FFWK has broad product lines, from various raw materials to QC/QA testing products, in its Laboratory chemicals to precisely meet various needs in all fields of study. FFWK also maintains a cell culture media production facility that follows the cGMP principle and underclass 100-100,000 management with humidity/temperature control.
With over 45 years of industry experience, FUJIFILM Irvine Scientific (FISI) is a worldwide leader in the innovation and manufacture of cell culture media. FISI offers a diverse portfolio of advanced cell culture media solutions including high-performance, proprietary chemically-defined media, rapid media screening, and optimization services, and close technical support designed to shorten development timelines and reduce costs. FISI adheres to both ISO and FDA regulations and currently operates dual cGMP manufacturing facilities in California, the USA, and Tokyo, Japan, with a third site due to be commissioned in 2021 in Tilburg, Netherlands.
Pall Corporation provides critical filtration, separation and purification solutions to meet the demanding needs of a broad spectrum of life sciences and industrial customers around the globe. Across 80 locations and 10,000 people worldwide, we are unified by a singular drive: to solve our customers' biggest fluid management challenges. And in doing so advance health, safety and environmentally responsible technologies.
For more info, please check: https://www.pall.com/en/biotech.html
Technology Showcase Sponsor
Astrea Bioseparations Ltd. (formerly Prometic Bioseparations Ltd) provides bioseparation products to the pharmaceutical and biotech markets, including chromatography adsorbents, custom adsorbent discovery and development services and pre-packed chromatography columns and column hardware.
Astrea Bioseparations is focused on purity and precision as we support customers working to Discover. Develop. and Deliver. quality products to the market that treat or potentially cure diseases. At Astrea Bioseparations every detail matters as our team works to create tailored solutions that streamline processes from early clinical to commercial phases.
A wholly-owned subsidiary of Gamma Biosciences, a life sciences tools platform supported by KKR, Astrea Bioseparations has R&D laboratories located at Cambridge, UK and manufacturing facilities located at the Isle of Man, British Isles, Joliette, Quebec, Canada and Stoughton, Massachusetts, USA.
For more information, please visit: https://www.astreabioseparations.com/
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development, and production activities in the industries we serve. One of our greatest strengths comes from having a global infrastructure that is strategically located to support the needs of our customers. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world.
Colder Products Company is the leading provider of quick disconnect couplings and connectors for plastic tubing. Founded in St. Paul, Minnesota in 1978, Colder has 250 employees and sales offices in nine countries. The solutions we provide are as varied as the customers we serve. A wide variety of industries use Colder quick disconnect couplings for the many benefits Colder’s products offer.
Pfanstiehl is the market leader of high purity / low endotoxin-low metal excipients for biologics, biosimilars, vaccines, cell culture media and injectable (liquid and lyophilized) formulations and supplies its products to nearly all of the leading global biopharmaceutical companies. Pfanstiehl was founded in 1919 and currently celebrating its 102nd anniversary year in 2021. Pfanstiehl is headquartered at Waukegan, IL, USA and has global presence with sales offices in Switzerland for EMEA & in Singapore for APAC.
Pfanstiehl has manufactured parenteral grade excipients for more than 50 years, and Pfanstiehl’s excipients are critical components in the majority of the top global blockbuster biopharmaceutical drugs & vaccines which have been administered to thousands of patients around the world. Pfanstiehl’s high purity, low endotoxin and low metals Carbohydrates & Amino acids are known as “best in class” due to their high purity, performance, consistency and quality attributes.
For more information, please visit: www.pfanstiehl.com
Amicogen, as Korea's leading industrial biotechnology company, was established to realize the value of contributing to human health and environmental protection.
Korea Biotechnology Industry Organization (KoreaBIO) is an association established as a result of the merger between three different industry associations in the biotechnology field in November 2008. KoreaBIO promotes communications among all bio-industry-related organizations and is striving to create a sustainable biotechnology industry ecosystem.
KoreaBIO is a central organization with around 500 members from major pharma & biotechnology companies to special members, representing the biotechnology industry of Korea. KoreaBIO also develops various training and policy-making programs to serve the member companies more efficiently, and also promotes cooperation, investment relations, and technological collaborations around the world.
Cold Chain Platform (CCP) is 100% focused on cold chain and logistics in the biopharmaceutical, life science, and healthcare industries. CCP services help global companies reach the right partners and get a firm foothold in the Asia Pacific. CCP works with global organizations to help them gain access to the APAC cold chain, logistics, and pharmaceutical market through a highly targeted audience.